← Back to patent-cliff list
CYTO-200 AIMS™ Program
Tier C — Watch / tradeCYTO-200 AIMS™ Program
Cytocom Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Multiple sclerosis, Crohn's disease, Fibromyalgia, COVID-19
Regional status
US
Phase II
2024-08-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CYTO-200 AIMS™ Program?
Approved indications include: Multiple sclerosis, Crohn's disease, Fibromyalgia, COVID-19.
When does the CYTO-200 AIMS™ Program patent expire?
No public expiry year is available for CYTO-200 AIMS™ Program yet; this page updates once verified.
How do I get a quote for CYTO-200 AIMS™ Program intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01